Objective: This systematic review and meta-analysis aimed to assess the pool estimates of extended-spectrum β-lactamases producing (ESBL-KP) and study their drug resistance profile by evaluating the studies from Nepal.
Methods: A literature search was carried out in PubMed, Google Scholar, and NepJOL to screen all articles on ESBL-KP published between 2011 and 2021 from Nepal. This review was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. Relevant data were extracted, and R language 4.2.0 software was used for statistical analysis.
Results: The pooled prevalence of was 5%, while the pooled prevalence of ESBL and multidrug resistance (MDR) in were 23% and 55%, respectively. Imipenem was the drug of choice (in vitro) against ESBL-KP infection.
Conclusion: Our analyses showed a high prevalence of ESBL-KP and their high resistance toward commonly used drugs. This study highlights the need for the development of new antibiotics for the management of ESBL-KP infections.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841864 | PMC |
| http://dx.doi.org/10.1177/11786361221145179 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!